bearish
Biosimilar Battlefield Update: It's Getting Uglier
685 Views28 Nov 2018 00:29
A confluence of negative news is causing sharp declines (or trading suspensions) in the share prices of Samsung Biologics Co., (207940...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
Kemp Dolliver, CFA
Founder
Price Chart(Sign Up to Access)
- Celltrion Healthcare: Well, We Were Warned24 Feb 2019
- Biosimilar Battlefield: The Remsima/Inflectra Warning06 Feb 2019
- The Smartkarma Week That Was in JP/KR: Nissan, J-Retail, Tesla/Panny, SK Rights, Biosimilars, Trade02 Dec 2018
- Biosimilar Battlefield Update: It's Getting Uglier28 Nov 2018
- Samsung BioLogics Update22 Oct 2018
- Celltrion: Understanding Inflectra's U.S. Challenges21 Sep 2018
- Biosimilar Battlefield: An Update15 Feb 2018
x